CPHI Milan 2026 is approaching. Chongqing Sintaho Pharmaceutical (Sintaho) will be at Booth 3K47 and looks forward to discussing new opportunities in API and C(D)MO collaboration with you.
As a one-stop C(D)MO service provider and API supplier, we leverage dual technology platforms to deliver full lifecycle services from molecular design to commercial supply:
Peptide Platform
SPPS/LPPS dual modes, covering linear peptides and complex cyclic peptides; expertise in side-chain conjugation, cyclization strategies, and comprehensive impurity profiling; purity ≥99.0% (HPLC); specialized in GLP-1 APIs.
Small Molecule Platform
OEB 4/5 containment production lines, focused on highly potent/cytotoxic APIs and ADC/XDC; expertise in chiral synthesis, GTI control, and gram-to-hundred-kilogram scale-up; custom development of payloads, linkers, and conjugates.
C(D)MO Services
Covering structural modification, regulatory filings (DMF/NDA/CEP/ASMF/ANDA), process scale-up, commercial supply, and long-term LCM; dual-track support for generic and innovative drug projects.
Sintaho operates approximately 55,000 m² of GMP facilities and has passed two consecutive FDA on-site inspections in August 2024 and October 2025.
Oct 6–8 | Fiera Milano | Booth 3K47
Schedule a meeting:
sales@sintaho.com
www.sintaho.com
If you are interested in C(D)MO collaboration for GLP-1, ADC/XDC, highly potent APIs, or complex peptides, feel free to comment or DM us to schedule a meeting. See you in Milan!
#CPHIMilan #CPHI2026 #API #CDMO #GLP1 #ADC #Pharma #Sintaho
